UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

 

 

FORM 6-K

 

 

 

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of April 2026

 

Commission File Number: 001-42526

 

Anbio Biotechnology

 

Friedrich-Ebert-Anlage 35-37, 60327
Frankfurt am Main,
Germany
+49 69870039170

(Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F ☒            Form 40-F ☐

 

 

 

 

 

 

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

 

In connection with the extraordinary general meeting of shareholders of Anbio Biotechnology (the “Company”), attached hereto and incorporated by reference herein are Notice of Meetings of Shareholders and Proxy Statement and Form of Proxy Card.

 

1

 

 

EXHIBIT INDEX

 

Exhibit No.   Description
99.1   Notice of Meetings of Shareholders and Proxy Statement
99.2   Form of Proxy Card for the Meeting of Shareholders of Class A Ordinary Shares
99.3   Form of Proxy Card for the Meeting of Shareholders of Class A Ordinary Shares and Class B Ordinary Shares
99.4   Amended and Restated Memorandum and Articles of Association

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Anbio Biotechnology
   
Date: April 27, 2026 By: /s/ Michael Lau
  Name:  Michael Lau
  Title: Chief Executive Officer

 

3